Showing 2151-2160 of 3361 results for "".
AbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigTopical Tretinoin: A Versatile Option for Adult Female Acne
https://practicaldermatology.com/issues/supplements/topical-tretinoin-a-versatileoption-for-adult-female-acne/23042/Findings of a roundtable discussion with leading acne experts on the benefits of retinoids for acne patients.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-8/23162/Diversity and Equity in Dermatology
https://practicaldermatology.com/topics/practice-management/diversity-and-equity-in-dermatology/23456/When Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://practicaldermatology.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
https://practicaldermatology.com/programs/cme/test-your-skills-and-learn-from-experts-on-il-13-inhibitors-in-moderate-to-severe-atopic-dermatitis/37624/Watch an expert-led case discussion on the role of IL-13 in moderate to severe atopic dermatitis and the efficacy on its inhibition through biologic therapies to achieve control.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-36/23740/Cosmeceuticals: Sunscreens
https://practicaldermatology.com/topics/general-topics/cosmeceuticals-sunscreens/21366/What you should know about the FDA's final ruling on sunscreen products and tips for understanding the variety of sun protection ingredients available to make more informed recommendations to patients.